Royalty Pharma (RPRX) Current Assets (2019 - 2026)

Royalty Pharma has disclosed Current Assets across 8 years of filings, most recently posting $1.4 billion for Q1 2026.

• Current Assets for Q1 2026 came in at $1.4 billion, down 22.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 billion (down 22.65% YoY), and the FY2025 annual result was $1.5 billion, down 15.21% from the prior year.
• Current Assets came in at $1.4 billion for Q1 2026 at Royalty Pharma, down from $1.5 billion in the prior quarter.
• In the past five years, Current Assets ranged from a high of $3.5 billion in Q2 2022 to a low of $1.3 billion in Q4 2023.
• The 5-year median for Current Assets is $1.8 billion (2025), against an average of $2.1 billion.
• Across the five-year window, Current Assets slumped 50.13% in 2023 and surged 41.43% in 2024, its largest moves.
• Royalty Pharma's Current Assets stood at $2.6 billion in 2022, then plunged by 50.13% to $1.3 billion in 2023, then jumped by 41.43% to $1.8 billion in 2024, then fell by 15.21% to $1.5 billion in 2025, then slipped by 6.69% to $1.4 billion in 2026.
• The last three Current Assets figures came in at $1.4 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.8 billion (Q3 2025), per Business Quant data.